Tavapadon

Overview

Tavapadon, sold under the brand name Juvmo, is a dopamine receptor agonist used for the treatment of Parkinson's disease. It is taken by mouth.[1][2] WP

Tavapadon was approved for medical use in the United States in September 2026.[3] WP

Uses, dosage and effects

Medical uses

Tavapadon is indicated for the treatment of Parkinson's disease in adults.[1] WP

Risks and side effects

Contraindications

Tavapadon has no contraindications.[1] WP

Side effects

Side effects of tavapadon may include nausea, headache, dizziness, fatigue or asthenia, dysgeusia, vomiting, dry mouth, and anxiety. Other potential but less common side effects include hypotension, orthostatic hypotension, impulsive control problems, compulsive behaviors, hallucinations, psychotic-like behaviors, and dyskinesia.[1] WP

Interactions

Interactions

Tavapadon is substrate for CYP3A4 and hence interacts with CYP3A4 inhibitors and inducers. In addition to being a CYP3A4 substrate, tavapadon is a CYP3A4 inducer and can interact with CYP3A4 substrates. It is also a CYP2C8 inhibitor and can interact with CYP2C8 substrates. Tavapadon is a BCRP inhibitor and can interact with substrates of this protein as well.[1] WP

Pharmacology

Pharmacodynamics

Tavapadon acts as a highly selective partial agonist of the dopamine D₁ receptor (Kᵢ = 9 nM; IA (Intrinsic activity) = 65%) and the dopamine D₅ receptor (Kᵢ = 13 nM; IA (Intrinsic activity) = 81%). It has no significant affinity or functional activity at the D₂-like receptors (D₂, D₃, D₄) (Kᵢ ≥ 4,870 to 6,720 nM). Tavapadon also shows biased agonism for Gₛ-coupled signaling at the D₁-like receptors.[2][4][5] WP

Pharmacokinetics

Peak levels of tavapadon are reached after approximately 2 to 4 hours with oral administration. It shows dose-proportional pharmacokinetics across its maintenance dosage range. Food does not significantly modify the pharmacokinetics of tavapadon and it can be taken without regard for food. The volume of distribution of tavapadon is 63.5 L. Its plasma protein binding is 93%, primarily to albumin. Tavapadon is primarily metabolized by CYP3A4. It has a major inactive metabolite. Unchanged tavapadon is excreted less than 1% in urine and feces. Its major inactive metabolite was excreted less than 5% in urine and feces. The elimination half-life of tavapadon is 25.5 hours.[1] WP

History

History

Tavapadon was developed by Cerevel Therapeutics, which acquired it from Pfizer in 2018.[6] WP

Legal status

Legal status

Tavapadon was approved for medical use in the United States in September 2026.[1][7] WP

Names

Tavapadon is the international nonproprietary name, and the United States Adopted Name.[8][9] WP

Tavapadon is sold under the brand name Juvmo.[1] WP

Chemistry

Formula

C19H16F3N3O3 PC

CAS number

1643489-24-0 PC

Molar mass (g/mol)

391.3 PC

IUPAC name (computed by PubChem)

1,5-dimethyl-6-[2-methyl-4-[[3-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]pyrimidine-2,4-dione PC

SMILES

CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C PC

InChIKey

AKQXQLUNFKDZBN-UHFFFAOYSA-N PC

PubChem CID

86764100

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other https://www.rxabbvie.com/pdf/juvmo_pi.pdf
2. Journal / agency Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S. Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease. CNS Neurol Disord Drug Targets. 2024. doi:10.2174/1871527322666230331121028 · PMID 36999711 · PMC10909821
3. Journal / agency Novel Drug Approvals for 2026. 28 September 2026
4. Journal / agency Cerri S, Blandini F. An update on the use of non-ergot dopamine agonists for the treatment of Parkinson's disease. Expert Opinion on Pharmacotherapy. December 2020. doi:10.1080/14656566.2020.1805432 · PMID 32804544
5. Journal / agency Hall A, Provins L, Valade A. Novel Strategies To Activate the Dopamine D₁ Receptor: Recent Advances in Orthosteric Agonism and Positive Allosteric Modulation. Journal of Medicinal Chemistry. January 2019. doi:10.1021/acs.jmedchem.8b01767 · PMID 30525590
6. Other AbbVie lands FDA approval for Cerevel-origin Parkinson's drug Juvmo. 28 September 2026
7. Other U.S. FDA Approves AbbVie's Juvmo (tavapadon) for Parkinson's Disease. 28 September 2026
8. Journal / agency World Health Organization. International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81. WHO Drug Information. 2019
9. Other https://searchusan.ama-assn.org/usan/documentDownload?uri=/unstructured/binary/usan/tavapadon.pdf

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.